BioSpace News Archive

MyoPax has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for its regenerative cell therapy in Exstrophy-Epispadias Complex (EEC).

G1 Therapeutics, Inc. will host a webcast and conference call to provide a financial and corporate update for the second quarter 2023 on Wednesday August 2, 2023, at 8:30 a.m. ET.

CordenPharma has created a new Technology & Science Advisory Board with eight world-class experts from academia and industry, who will provide strategic guidance and scientific expertise to drive forward the company’s continued growth and innovation.

ViroCell Biologics, a specialist Contract Development and Manufacturing Organisation in cell and gene therapy clinical trials, announces the appointment of Brian Collins as Chief Financial Officer.

Vantage Biosciences, a new company launched by ALSA Ventures which invests in novel therapeutics for unmet medical needs, is pleased to announce the acquisition of lead asset VX-01, an oral therapy targeting diabetic eye diseases, set to enter Phase 2 clinical development in mid-2024.

Myolex® Inc. announced that Dave Dickinson has been named the company’s Chief Executive Officer and Board Director.

Just one week after returning from Inspired Spine’s training lab in Germany, the internationally renowned neurosurgeon, Dr. Hamid Abbasi, showcased the pioneering Trans-Kambin OLLIF Procedure in multiple states by presenting to the Seattle Science Foundation and leading a cadaver lab at Swedish Hospital last Saturday, July 22nd.

Thermo Fisher Scientific Inc., the world leader in serving science, reported its financial results for the second quarter ended July 1, 2023.

Quest Diagnostics Incorporated, the world’s leading provider of diagnostic information services, announced financial results for the second quarter ended June 30, 2023.

Merck, known as MSD outside of the United States and Canada, and Moderna, Inc. announced the initiation of the pivotal Phase 3 randomized V940-001 clinical trial evaluating V940, an investigational individualized neoantigen therapy, in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, as an adjuvant treatment in patients with resected high-risk melanoma.